Focus is on Streamlining and Speeding Decision-Making in Rapidly Changing
                           Healthcare Marketplace
       Vice Chairman David Shedlarz Assumes Expanded Responsibilities

    NEW YORK, Aug. 15 /PRNewswire-FirstCall/ -- In a letter to Pfizer
colleagues, Chief Executive Officer Jeffrey B. Kindler today announced a
new leadership organization to streamline the company's operations and
speed decision-making in a rapidly changing healthcare marketplace.
    Kindler, who was named Pfizer's CEO on July 28, said, "Our new
organizational structure builds on the strengths of our company while
responding to the accelerating changes in the environment in which we
operate. This will put us in the best position to capitalize quickly on the
enormous opportunities ahead of us through increasing support for
successful new medicines, forging partnerships with key customers, entering
into co-promotion and licensing agreements, investing in new technologies
to add value to our core product offerings, or acquiring new products and
services from outside the company."
    Pointing to changes in the company's operating environment, Mr. Kindler
told Pfizer colleagues that "science is creating wholly new ways to treat
disease; regulators and payers are more demanding; and patients and their
families are using newly available information to take more control over
their healthcare decisions." He added that Pfizer must "become more agile
and entrepreneurial, embracing the spirit of a small company while
exploiting the advantages of our unmatched scale and reach."
    Mr. Kindler said that David Shedlarz, vice chairman, will be assuming
expanded responsibilities. Mr. Shedlarz's additional responsibilities will
include Pfizer Global Manufacturing, and worldwide strategic planning,
licensing and business development and technology. "To his new role as my
principal deputy, David brings strategic insight, years of experience in
our industry and many important accomplishments achieved during his
distinguished career at Pfizer," said Mr. Kindler. "David is a Pfizer
leader with a deep and abiding commitment to our mission and the ability to
bring colleagues together and inspire them to work toward a common goal. He
is well-known in the investment community, where he has been instrumental
in building Pfizer's reputation for financial transparency and excellence
in reporting. One major focus for David will be to apply technology across
the company both to improve productivity as well as to help develop new
products and services that enhance the value of our medicines."
    The new Pfizer Executive Leadership Team, which Mr. Kindler said
"brings together all the essential elements necessary for us to compete in
this new era for healthcare," includes executives with many years of
pharmaceutical experience at Pfizer and elsewhere. This group will
constitute the senior-most leadership, management and decision-making body
of the company. It consists of Mr. Shedlarz; PGRD President John LaMattina,
whose role reflects the crucial importance of science to Pfizer's future;
Worldwide Pharmaceuticals Operations President Ian Read, who will lead an
integrated global unit; Chief Medical Officer Dr. Joe Feczko; Worldwide
Talent Development and Human Resources leader Sylvia Montero; General
Counsel Allen Waxman; and Worldwide Public Affairs and Policy leader Rich
Bagger.
    Pointing to the advantages of a streamlined leadership structure, Mr.
Kindler told his colleagues that among the opportunities the company will
pursue are:
    * Continuing to grow its portfolio of research opportunities, expanding
      Pfizer's presence in new disciplines such as genomics and biologics;

    * Building upon a broad, deep and diverse pool of talent drawn both from
      outstanding Pfizer colleagues as well as from individuals outside the
      company;

    * Accelerating the development of patient support and compliance programs
      to enhance the value of Pfizer medicines to patients; and

    * Harnessing technology for the company's competitive advantage, both
      internally and with respect to the company's customer offerings.
    Mr. Kindler also said that Vice Chairman Karen Katen has reflected on
both her professional and personal goals, and she will be leaving the
company to pursue other opportunities. She will provide advice and
leadership over the next several months in several important areas,
including Pfizer Health Solutions and Pfizer Healthy Directions, as well as
healthcare policy. "I know I join with all Pfizer colleagues in expressing
the deepest admiration and thanks to Karen for her dedication and her many
contributions to our company. Over more than three decades, Karen has
played a critical role in the growth of Pfizer to world leadership in
pharmaceuticals. But just as important, Karen reflects Pfizer's values --
and she has always demonstrated strong and effective leadership at the
company throughout her career."
    Mr. Kindler asked Pfizer colleagues to go forward with their continued
strong commitment to help patients live longer and healthier lives, because
"we know there remain more people around the world looking to us for new
treatments and many cures."
    Mr. Kindler's memo to colleagues and biographies of members of Pfizer's
new Executive Leadership Team are available on http://www.pfizer.com.

Link to this page:

  

http://www.prnewswire.com/comp/688250.html /
CONTACT:
Andy McCormick of Pfizer Inc, +1-212-733-5469

---

---

Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content.
Terms and conditions, including restrictions on redistribution, apply.
Copyright © 1996- PR Newswire Association LLC. All Rights Reserved.
A United Business Media company.